Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells
- 344 Downloads
Gastric cancer (GC) is the second most common leading cause of cancer-related death. Cancer stem cell (CSC) with the mark of CD44 played an important role in GC. rMETase was wildly exploited as chemotherapeutic option for GC. Polymers synthetic nanoparticle drug delivery systems have been commonly used for cancer therapy. With the decorating of Hyaluronic acid (HA), a receptor of CD44, nanoparticles exhibit with good biocompatibility and aqueous solubility.
The characteristic of nanoparticles (NPs) was analyzed by TEM and DLS. The viability and proliferation of GC cells were examined by MTT assays. The levels of CD44, Cyt C, and c-caspase 3 were examined by Western blot. The level of ROS was measured by DCFH-DA assays. The morphology of tissues was detected using hematoxylin–eosin (H&E) stain. Nude mice xenograft models were used to evaluate the effect of HA-PAMAM-Au-METase on GC.
The transfection of rMETase carried by HA-G5 PAMAM-Au visibly inhibited the proliferation and tumorsphere formation of GC cells through obviously enhancing METase activity. Elevation of METase activity suppressed the proliferation of CD44(+) GC cells through down-regulating MET in cellular supernatant that resulted in the increase of Cyc C and ROS levels. The number of CD44(+) GC cells in nude mice injected with G5 PAMAM-Au-METase decorated by HA was markly declined resulting in the inhibition of tumor growth.
HA-G5 PAMAM-Au-METase significantly suppressed tumor growth of GC by targeted damaging the mitochondrial function of CD44(+) gastric CSCs.
KeywordsHA-PAMAM-Au-METase CD44 Gastric cancer stem cells
This work was supported by The National Natural Science Foundation of China (Nos. 81560492 and 81760549).
Compliance with ethical standards
Conflict of interest
All authors declare that there is no conflict of interest.
Research involving human participants and/or animals
Yes, animals were involved in the present study.
The study was approved by ethics committee of hospital.
The study was undertaken with the hospital’s consent.
- Baker JR Jr (2009) Dendrimer-based nanoparticles for cancer therapy, Hematol Am Soc Hematol Educ Program, 708–719Google Scholar
- de Andrade NP, Rodrigues MF, Rodini CO, Nunes FD (2016) Cancer stem cell, cytokeratins and epithelial to mesenchymal transition markers expression in oral squamous cell carcinoma derived from ortothopic xenoimplantation of CD44(high) cells, Pathology Research & Practice, 213:235–244Google Scholar
- Kuo WY, Hwu L, Wu CY, Lee JS, Chang CW, Liu RS (2017) STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast CancerGoogle Scholar
- Liang X, Li X, Chang J, Duan Y, Li Z (2013) Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer-targeted gene delivery. Langmuir 29:8683–8693Google Scholar
- Ma N, Wu FG, Zhang X, Jiang YW, Jia HR, Wang HY, Li YH, Liu P, Gu N, Chen Z, Shape-dependent radiosensitization effect of gold nanostructures in cancer radiotherapy: comparison of gold nanoparticles, NanospikesGoogle Scholar
- Machover D, Zittoun J, Saffroy R, Broët P, Giraudier S, Magnaldo T, Goldschmidt E, Debuire B, Orrico M, Tan Y (2002) Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis. Can Res 62:4685–4689Google Scholar
- Miki K, Alrefaie W, Xu M, Jiang P, Tan Y, Bouvet M, Zhao M, Gupta A, Chishima T, Shimada H (2000a) Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Can Res 60:2696–2702Google Scholar
- Uthaman S, Zheng S, Han J, Choi YJ, Cho S, Nguyen VD, Park JO, Park SH, Min JJ, Park S (2015) Preparation of engineered salmonella typhimurium-driven hyaluronic-acid-based microbeads with both chemotactic and biological targeting towards breast cancer cells for enhanced anticancer therapy. Adv Healthcare Mater 5:288–295CrossRefGoogle Scholar
- Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Can Res 54:6228Google Scholar
- Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Zhang M (2011) Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomed 6:1747Google Scholar